Isis Pharmaceuticals, Inc.

Antisense Therapeutics Limited

National University of Singapore

James G Karras

Susan M Freier

Kenneth W Dobie

C Frank Bennett

Susan Gregory

Brett P Monia

Robert McKay

Timothy A Vickers

Jeffrey R Crosby

Mausumee Guha

Muthiah Manoharan

Jacqueline R Wyatt

Nicholas M Dean

Brenda F Baker

William A Gaarde

George Tachas

Gregory E Hardee

Ian Popoff

Frank C Bennett

Scott Cooper

Susan Kelly

David Tung

Stanley T Cooke

Sujatha Dokka

Wai Shiu Fred Wong

A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin &#x3b1;4 comprising administering to the animal a composition comprising from. 0.001 to 1000 &#x3bc;g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin &#x3b1;4.

Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions

Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.

Modulation of stat5 expression

Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

Antisense oligonucleotide modulation of STAT3 expression

The present invention relates to compositions and methods which enhance the delivery of nucleic acids and other nucleosidic moieties via topical routes of administration. The invention relates to the use of an aqueous solution to preferentially deliver nucleic acids preferentially to hair follicles. The invention relates to a method of inhibiting hair growth comprising administration of a nucleic acid preferentially to a hair follicle.

Compositions and methods for topical delivery of oligonucleotides

Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-&#x3b1;, airway hyperresponsiveness, and/or pulmonary inflammation.

Compositions and their uses directed to IL-4R alpha

Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.

Antisense modulation of p38 mitogen activated protein kinase expression

Modulation of STAT5 expression

Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of TARC, airway hyperresponsiveness, and/or pulmonary inflammation.

Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)

Compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.

Oligonucleotide compositions and methods for the modulation of the expression of B7 protein

Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.

Antisense modulation of B7 protein expression

Growing community of inventors

San Marcos, CA, United States of America

James G Karras